Prostate Cancer Mortality Progress Stalls, Prompting Questions About PSA Policies

Tony Berberabe, MPH @OncBiz_Wiz
Published: Wednesday, Jan 09, 2019
Serban Negoita, MD, DrPH

Serban Negoita, MD, DrPH
An analysis of prostate cancer trends adjusted for delays in reporting by stage of disease showed that incidence of late-stage disease increased from 2010 to 2014 after a decline in prostate-specific antigen (PSA) use. Additionally, previously declining mortality trends have flattened raising concerns among investigators at the Centers for Disease Control and Prevention, National Cancer Institute (NCI), American Cancer Society, and other cancer registry associations.1

 

Figure. US Prostate Cancer Mortality Rates: All Stages

Figure. US Prostate Cancer Mortality Rates: All Stages

 
After the peak, a greater decline in mortality was observed in black men (APC, –2.5) compared with white men (APC, –0.7). Between 2001 and 2015, the rate of decline among black men increased to an APC of –4.2. However, after a more sustained fall between 1994 and 1999 (APC, –4.3), the mortality decline slowed among white men (APC, –3.3) and then leveled off after 2013 (APC –0.4 [statistically nonsignificant]).
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 3rd Annual International Congress on Oncology & Pathology™Aug 30, 20201.5
Community Practice Connections™: ASCO Direct™ Highlights – 2019 Official Annual Meeting ReviewAug 30, 20201.5
Publication Bottom Border
Border Publication
x